Clinical Trials Logo

Vulvar Intraepithelial Neoplasia clinical trials

View clinical trials related to Vulvar Intraepithelial Neoplasia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05463796 Recruiting - Lung Cancer Clinical Trials

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Start date: April 25, 2023
Phase:
Study type: Observational [Patient Registry]

This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. - The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal. - The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.

NCT ID: NCT05104099 Recruiting - Clinical trials for Vulvar Intraepithelial Neoplasia

Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia

PhotodiVIN
Start date: November 29, 2021
Phase: Phase 2
Study type: Interventional

This study is a single-center propsective clinical trial to assess the ability of fluorescence techniques to mark high-grade vulvar intraepithelial neoplasias including high-grade vulvar squamous intraepithelial lesions and differentiated vulvar intraepithelial neoplasias following 3 hours Metvixia application.

NCT ID: NCT05045755 Recruiting - Cervical Cancer Clinical Trials

The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

Start date: April 13, 2021
Phase:
Study type: Observational

The primary objective of this study is to evaluate the durability of protection and immuno-persistence of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine administered in females aged 18-45 years.

NCT ID: NCT04969445 Recruiting - Cervical Cancer Clinical Trials

The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

Start date: March 30, 2021
Phase:
Study type: Observational

The primary objective of this study is to evaluate the durability of protection of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine administered in females aged 18-45 years.